BRPI0907453A2 - Compostos, uso e preparação dos mesmos - Google Patents

Compostos, uso e preparação dos mesmos

Info

Publication number
BRPI0907453A2
BRPI0907453A2 BRPI0907453-8A BRPI0907453A BRPI0907453A2 BR PI0907453 A2 BRPI0907453 A2 BR PI0907453A2 BR PI0907453 A BRPI0907453 A BR PI0907453A BR PI0907453 A2 BRPI0907453 A2 BR PI0907453A2
Authority
BR
Brazil
Prior art keywords
compounds
preparation
Prior art date
Application number
BRPI0907453-8A
Other languages
English (en)
Inventor
Annika Jenmalm Jensen
Fredrik Lehmann
Björn M Nilsson
Erik Nordling
Vendela Parrow
Original Assignee
Akinion Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akinion Pharmaceuticals Ab filed Critical Akinion Pharmaceuticals Ab
Publication of BRPI0907453A2 publication Critical patent/BRPI0907453A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0907453-8A 2008-02-01 2009-01-28 Compostos, uso e preparação dos mesmos BRPI0907453A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0800250 2008-02-01
US12303908P 2008-04-04 2008-04-04
SE0801185 2008-05-21
PCT/EP2009/050931 WO2009095399A2 (en) 2008-02-01 2009-01-28 Pyrazine derivatives and their use as protein kinase inhbitors

Publications (1)

Publication Number Publication Date
BRPI0907453A2 true BRPI0907453A2 (pt) 2015-07-14

Family

ID=40527384

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907453-8A BRPI0907453A2 (pt) 2008-02-01 2009-01-28 Compostos, uso e preparação dos mesmos

Country Status (18)

Country Link
US (2) US8436171B2 (pt)
EP (2) EP2671876A3 (pt)
JP (2) JP5562256B2 (pt)
KR (1) KR101599082B1 (pt)
CN (1) CN101970418B (pt)
AU (1) AU2009209633C1 (pt)
BR (1) BRPI0907453A2 (pt)
CA (1) CA2713553A1 (pt)
CY (1) CY1115400T1 (pt)
DK (1) DK2252597T3 (pt)
ES (1) ES2459297T3 (pt)
HR (1) HRP20140547T1 (pt)
MX (1) MX2010007973A (pt)
PL (1) PL2252597T3 (pt)
PT (1) PT2252597E (pt)
RU (1) RU2493152C2 (pt)
SI (1) SI2252597T1 (pt)
WO (1) WO2009095399A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010007973A (es) * 2008-02-01 2010-11-09 Akinion Pharmaceuticals Ab Derivados de pirazina y su uso como inhibidores de proteina cinasa.
HUE045270T2 (hu) 2010-01-05 2019-12-30 Inst Nat Sante Rech Med FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
WO2013089636A1 (en) * 2011-12-15 2013-06-20 Akinion Pharmaceuticals Ab Processes for manufacturing of a kinase inhibitor
CN109602734A (zh) * 2012-03-14 2019-04-12 印第安纳大学研究及科技有限公司 用于治疗白血病的化合物和方法
HRP20180037T1 (hr) 2012-04-17 2018-03-23 Fujifilm Corporation Heterociklični spoj koji sadrži dušik ili njegovu sol
UY34807A (es) * 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
KR101744033B1 (ko) 2013-10-16 2017-06-07 후지필름 가부시키가이샤 함질소 복소환 화합물의 염 또는 그 결정, 의약 조성물 및 flt3 저해제
BR112017002001B1 (pt) * 2014-07-31 2022-10-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compostos e composição farmacêutica
EP3195866B1 (en) 2014-08-22 2020-11-18 FUJIFILM Corporation Pharmaceutical composition for treating flt3 mutation-positive cancer, mutant flt3 inhibitor and uses thereof
CN105985322A (zh) * 2015-03-03 2016-10-05 苏州翔实医药发展有限公司 氨基吡嗪化合物及其用途
JP6412471B2 (ja) 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
JP2020519665A (ja) 2017-05-17 2020-07-02 アンセルム(アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル) オピオイドによる痛みの処置を改善する為のflt3阻害剤
CN111163780A (zh) 2017-07-18 2020-05-15 诺维逊生物股份有限公司 作为腺苷拮抗剂的杂环化合物
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
CN110483366B (zh) * 2018-05-14 2022-09-16 中国医学科学院药物研究所 吲哚类化合物及其制备方法、药物组合物和用途
WO2020150676A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
JP2022517418A (ja) * 2019-01-18 2022-03-08 ニューベイション・バイオ・インコーポレイテッド アデノシンアンタゴニストとしてのヘテロ環式化合物
AU2020208644A1 (en) 2019-01-18 2021-08-26 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN112574192B (zh) * 2020-12-24 2021-10-01 烟台大学 氨基酸衍生联噻唑-色胺类抗癌化合物和应用
KR20250075303A (ko) * 2023-11-21 2025-05-28 (주)신테카바이오 크레놀라닙 또는 이의 약학적으로 허용 가능한 염을 포함하는 건선의 예방 또는 치료용 조성물
KR20250075302A (ko) * 2023-11-21 2025-05-28 (주)신테카바이오 크레놀라닙 또는 이의 약학적으로 허용 가능한 염을 포함하는 아토피 피부염의 예방 또는 치료용 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (pt) * 1992-04-03 1994-06-21 Ciba Geigy Ag
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
US20040102455A1 (en) * 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
CA2486183C (en) 2002-05-23 2012-01-10 Cytopia Pty Ltd. Protein kinase inhibitors
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
EP1670794A2 (en) * 2003-09-30 2006-06-21 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20080194574A1 (en) * 2003-12-16 2008-08-14 Axxima Pharmaceuticals Ag Pyrazine Derivatives As Effective Compounds Against Infectious Diseases
CA2561831A1 (en) 2004-04-13 2005-12-22 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
CA2660560A1 (en) * 2006-08-16 2008-02-21 Boehringer Ingelheim International Gmbh Pyrazine compounds, their use and methods of preparation
US8461161B2 (en) * 2006-11-15 2013-06-11 Ym Biosciences Australia Pty Ltd Substituted pyrazines as inhibitors of kinase activity
MX2010007973A (es) * 2008-02-01 2010-11-09 Akinion Pharmaceuticals Ab Derivados de pirazina y su uso como inhibidores de proteina cinasa.

Also Published As

Publication number Publication date
EP2671876A2 (en) 2013-12-11
KR101599082B1 (ko) 2016-03-02
US20110098310A1 (en) 2011-04-28
HK1149268A1 (en) 2011-09-30
AU2009209633A1 (en) 2009-08-06
WO2009095399A3 (en) 2009-10-01
EP2252597B1 (en) 2014-03-19
WO2009095399A2 (en) 2009-08-06
PL2252597T3 (pl) 2014-09-30
US8436171B2 (en) 2013-05-07
JP2014148522A (ja) 2014-08-21
HRP20140547T1 (hr) 2014-07-18
KR20100116599A (ko) 2010-11-01
CN101970418B (zh) 2013-07-03
AU2009209633C1 (en) 2014-01-23
RU2493152C2 (ru) 2013-09-20
US20130203774A1 (en) 2013-08-08
JP2011510948A (ja) 2011-04-07
EP2252597A2 (en) 2010-11-24
PT2252597E (pt) 2014-04-30
JP5562256B2 (ja) 2014-07-30
CY1115400T1 (el) 2017-01-04
SI2252597T1 (sl) 2014-07-31
CN101970418A (zh) 2011-02-09
EP2671876A3 (en) 2014-02-05
AU2009209633B2 (en) 2013-07-18
RU2010136653A (ru) 2012-03-10
CA2713553A1 (en) 2009-08-06
ES2459297T3 (es) 2014-05-08
DK2252597T3 (da) 2014-04-28
MX2010007973A (es) 2010-11-09

Similar Documents

Publication Publication Date Title
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
BRPI0918502A2 (pt) aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos
BR112012002349A2 (pt) composto,e, uso do mesmo
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0821668A2 (pt) Uso
BR112012003661A2 (pt) "compostos de biarila e métodos de uso dos mesmos."
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
SMT201500218B (it) Composti aril-fenil-solfonammido-cicloalchile e loro uso
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0821276A2 (pt) Produto, e, uso do produto
BR112013016772A2 (pt) composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0915134A2 (pt) composto, e, uso de um composto
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0907365A2 (pt) Composição antimicrobiana e uso
BRPI1007494A2 (pt) composto e uso do mesmo
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0907572A2 (pt) Derivados de fluorglicosídeos aromáticos, fármacos compreendendo os referidos compostos e uso dos mesmos
BRPI0813457A2 (pt) Composto de organoenxofre contendo halogênio e uso do mesmo
BRPI0913188A2 (pt) moduladores de receptores 5-ht3, métodos de fabricação, e uso dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL